In the past years, it has been observed that, there are many kinds of drug-eluting stents available in the market, which has strongly developed coronary artery disease (CAD) revascularization. This is majorly due to the declining rate of target lesion revascularization (TLR) and major adverse cardiac events (MACE). Permanent drug-eluting stents coated with anti-proliferative agents reduce the incidence of restenosis and target lesion revascularization by inhibition of neointimal hyperplasia. Permanent drug-eluting stents with permanent polymers do not degrade in vivo, and may raise the probability of polymer hypersensitivity or stent-related delayed arterial healing. Permanent drug-eluting stents have a lower rate of clinical trials due to the introduction of next-generation drug-eluting stents. Next-generation drug-eluting stents are a modification of previous developed permanent drug-eluting stents, which offer enhanced drug delivery and stent flexibility. Permanent drug-eluting stents generally consist of three components; mainly a permanent metallic scaffold, an antiproliferative drug, and the polymer.
The increasing geriatric population is considered as the primary factor in driving the growth of the global permanent drug-eluting stents market. This is due to the high risk of developing arterial disorders in the geriatric population on a global level. Moreover, the rising prevalence of obesity and unhealthy lifestyle related to atherosclerosis are also major factors responsible for the growth of the global permanent drug-eluting stents market. Furthermore, rising healthcare expenditure and increasing awareness in low middle-income countries are also some of the factors which are responsible for driving the growth of the global permanent drug-eluting stents market. In addition, rising government support and growing research and development activities are also boosting the growth of the permanent drug-eluting stents market. However, the availability of alternative therapies is considered as a major obstacle hampering the growth of the global permanent drug-eluting stents market. Furthermore, the increasing inclination of patients for drugs over surgical procedures is also limiting the growth of the global permanent drug-eluting stents market.
The global market for permanent drug-eluting stents is segmented on the basis of polymer type, end user, and geography.
- Based on polymer type, the global permanent drug-eluting stents market is segmented into:
- Bioabsorbable Polymers
- Durable Polymers
- Based on end user, the global permanent drug-eluting stents market is segmented into:
- Ambulatory Surgical Centers
After the introduction of permanent drug-eluting stents, numerous technological advancements have been observed to generate a good product offering which provides the accurate delivery of drug and caters to safety concerns. Bioabsorbable polymer-based permanent drug-eluting stents are considered to be safe and effective in actual practice. Based on end users, the global permanent drug-eluting stents market is segmented into hospitals, ambulatory surgical centers, and clinics. It is projected that, among all the end users, hospitals are anticipated to hold the maximum market share in the global permanent drug-eluting stents market.
Request for Sample Report @ https://www.persistencemarketresearch.com/samples/24313
On the basis of geography, the global permanent drug-eluting stents market is segmented into six key regions, viz. North America, Latin America, Europe, Asia Pacific excluding China, China, and the Middle East & Africa. The North American permanent drug-eluting stents market is projected to register the maximum market share in the global permanent drug-eluting stents market, followed by Europe, due to the high incidence and prevalence of coronary artery diseases and the presence of major permanent drug-eluting stent players in the region. Furthermore, the presence of well-trained healthcare professionals also contributes to the growth of the permanent drug-eluting stents market. The permanent drug-eluting stents market in Asia Pacific is expected to grow at a maximum CAGR over the forecast period, due to improving healthcare facilities and growing investments from both, public and private bodies. However, the permanent drug-eluting stents markets in Latin America and the Middle East and Africa are anticipated to experience steady growth over the forecast period.
Request for view TOC @ https://www.persistencemarketresearch.com/toc/24313
Some of the key players in the global permanent drug-eluting stents market are Boston Scientific Corporation, Terumo Corporation, Abbott Laboratories, OSSTEM CARDIOTEC Co., Ltd., and others. In the permanent drug-eluting stents market, a trend has been observed that, leading market players are majorly focusing on expanding their geographical presence and investing in product development. Furthermore, the adoption of various strategies is observed by various players in the permanent drug-eluting stents market to grow at a significant rate.